NCT02419391View on ClinicalTrials.gov

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

PHASE1CompletedINTERVENTIONAL

Enrollment

63

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

May 31, 2016

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

MVA BN RSV

Liquid frozen suspension of MVA-mBN294B

OTHER

Placebo

Tris Buffered Saline, sterile

Trial Locations (1)

66219

Johnson County Clin-Trials (JCCT), Lenexa

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

lead

Bavarian Nordic

INDUSTRY

NCT02419391 - Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine | Biotech Hunter | Biotech Hunter